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CGVHD is a major complication with high morbidity and
mortality post allogeneic hematopoietic cell transplants
(HCT). An IRB approved retrospective review of 338 pediatric
survivors of HCT (>1yr) between 1992-2012 at Lurie Chil-
dren’s Hospital was performed. Forty nine patients met NIH
criteria for moderate to severe CGVHD. Patient characteris-
tics are shown in table 1. The prevalence of CGVHD was 14%.
The median time from transplant to diagnosis of CGVHD was
0.49 (0-9.6) years. Hazard ratios (HR) & 95% CI for OS by Cox
Log rank analysis were: related vs. unrelated donor (2.54, CI
1.11-5.7) Fig 1; BM vs. PBSC (0.33, CI 0.13-0.85) Fig 2; degree
of matching (0.56, CI 0.20-1.5) Fig 3 and Myeloablative con-
ditioning (MCR) vs. Reduced Intensity (RIC) (1.9, CI 0.80-4.8
p¼0.14). The OS at 5 years was 55% and at 10 years 46%. The
major causes of mortality were: CGVHD (6), Infection (9),
Disease progression (2), Cardiac (2), renal failure (1) and
unknown (2). Factors associated with a poorer survival areTable 1
Patient Characteristics
Age (median) 11 + 6.4 y
Gender
M/F 33/16
Ethnicity
Caucasian 31
Hispanic 8
African American 8
Other 2
Diagnosis
Malignancy 40
Other 9
Stem Cell Source
Related 25
Un-related 24
Marrow 10
PBSC 36
UCB 3
CD 34 cell dose (median) 6.7 X106/kg (.26-29)
HLA Matched
Matched 32
1 Antigen Mismatch 13
2 Antigen Mismatch 4
Conditioning Regimen
Myeloablative 34
Reduced intensity 15
Disease Status at transplant
(Malignancy patients)
CR 1 12
CR2 21
CR3 7
CGVHD organ involvement
Moderate 12
Severe 37
Figure 3. OS by Degree of Matchingdegree of matching (2 antigen mismatches), related vs.
unrelated and BM vs. PBSC. We could not ﬁnd a difference in
OS between RIC vs. MCR. The main cause of death was
infection and progression of CGVHD (pulmonary).492
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